CBRN Division, Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organization (DRDO), India.
Int J Radiat Biol. 2023;99(12):1865-1878. doi: 10.1080/09553002.2023.2242929. Epub 2023 Aug 29.
Radiation-induced gastrointestinal injury (RIGI) is a serious side effect of abdominal and pelvic radiotherapy, which often limits the treatment of gastrointestinal and gynaecological cancers. RIGI is also observed during accidental radiological or nuclear scenarios with no approved agents available till date to prevent or mitigate RIGI in humans. Trichostatin A (TSA), an epigenetic modulator, has been currently in clinical trials for cancer treatment and is also well known for its antibiotic and antifungal properties.
In this study, partial body (abdominal) irradiation mice model was used to investigate the mitigative effect of TSA against gastrointestinal toxicity caused by gamma radiation. Mice were checked for alterations in mean body weight, diarrheal incidence, disease activity index and survival against 15 Gy radiation. Structural abnormalities in intestine and changes in microbiota composition were studied by histopathology and 16S rRNA sequencing of fecal samples respectively. Immunoblotting and biochemical assays were performed to check protein nitrosylation, expression of inflammatory mediators, infiltration of inflammatory cells and changes in pro-inflammatory cytokine.
TSA administration to C57Bl/6 mice improved radiation induced mean body weight loss, maintained better health score, reduced disease activity index and promoted survival. The 16S rRNA sequencing of fecal DNA demonstrated that TSA influenced the fecal microbiota dynamics with significant alterations in the Firmicutes/Bacteriodetes ratio. TSA effectively mitigated intestinal injury, down-regulated NF-κB, Cox-2, iNOS expression, inhibited PGE2 and protein nitrosylation levels in irradiated intestine. The upregulation of NLRP3-inflammasome complex and infiltrations of inflammatory cells in the inflamed intestine were also prevented by TSA. Subsequently, the myeloperoxidase activity in intestine alongwith serum IL-18 levels was found reduced.
These findings provide evidence that TSA inhibits inflammatory mediators, alleviates gut dysbiosis, and promotes structural restoration of the irradiated intestine. TSA, therefore, can be considered as a potential agent for mitigation of RIGI in humans.
腹部和盆腔放射治疗会导致放射性胃肠道损伤(RIGI),这是一种严重的副作用,常限制胃肠道和妇科癌症的治疗。在意外的放射学或核事件中也会观察到 RIGI,目前尚无可用的药物来预防或减轻人类的 RIGI。曲古抑菌素 A(TSA)是一种表观遗传调节剂,目前正在进行癌症治疗的临床试验,并且以其抗生素和抗真菌特性而闻名。
本研究采用腹部局部照射小鼠模型,研究 TSA 对γ射线引起的胃肠道毒性的缓解作用。通过检查 15Gy 辐射后小鼠的平均体重变化、腹泻发生率、疾病活动指数和存活率来评估 TSA 的作用。通过组织病理学和粪便样本 16S rRNA 测序分别研究肠道结构异常和微生物群落组成的变化。通过免疫印迹和生化分析检查蛋白质硝化、炎症介质表达、炎症细胞浸润和促炎细胞因子变化。
TSA 给药可改善 C57Bl/6 小鼠辐射引起的平均体重减轻,保持更好的健康评分,降低疾病活动指数并提高存活率。粪便 DNA 的 16S rRNA 测序表明,TSA 影响粪便微生物群动态,Firmicutes/Bacteriodetes 比值发生显著变化。TSA 有效减轻了肠道损伤,下调了 NF-κB、Cox-2 和 iNOS 的表达,抑制了 PGE2 和放射性肠道中的蛋白质硝化水平。TSA 还可预防 NLRP3 炎性体复合物的上调和炎性细胞在炎症肠道中的浸润。随后,发现肠道髓过氧化物酶活性和血清 IL-18 水平降低。
这些发现提供了证据,表明 TSA 抑制炎症介质,缓解肠道菌群失调,并促进辐射损伤肠道的结构恢复。因此,TSA 可被视为减轻人类 RIGI 的潜在药物。